41.8°C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases

Cancer Immunology, Immunotherapy

Volumn 51, Issue 11-12, 2002, Pages 603-613

  Atanackovic, Djordje ^a,b   Nierhaus, Axel ^a   Neumeier, Michael ^a   Hossfeld, Dieter K ^a   Hegewisch Becker, Susanna ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Immunotherapy; NK T cell; T cell; Tumor immunity

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; CELL PROTEIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

ARTICLE; BILE DUCT CARCINOMA; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CELL PROLIFERATION; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; HUMAN; HYPERTHERMIA; LEUKOCYTE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; OVARY CARCINOMA; PERIPHERAL LYMPHOCYTE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; T LYMPHOCYTE ACTIVATION; TEMPERATURE; BLOOD; HYPERTHERMIC THERAPY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MULTIMODALITY CANCER THERAPY; NEOPLASM; T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; HYPERTHERMIA, INDUCED; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036885152     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0327-x     Document Type: Article

References (63)

1. Ahlers O, Boehnke T, Kerner T, Deja M, Keh D, Löffel J, Hildebrandt B, Riess H, Wust P, Pappert D, Gerlach H (1999) Leukocyte alterations during hyperthermia. Br J Anaesth 80(1):88
2. Ahlers O, Hildebrandt B, Löffel J, Boehnke T, Kerner T, Deja M, Keh D, Wust P, Gerlach H, Riess H (1999) Whole body hyperthermia-induced stress reactions. Onkologie 22:47
3. + tumor-infiltrating lymphocytes. J Exp Med 173:647
4. + activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: Correlation with survival following active specific immunotherapy. Int J Cancer 61:470
5. Craston R, Koh M, Mc Dermott A, Ray N, Prentice HG, Lowdell MW (1997) Temporal dynamics of CD69 expression on lymphoid cells. J Immunol Methods 209:37
6. D'Ambrosio D, Trotta R, Vacca A, Frati L, Santoni A, Gulino A, Testi R (1993) Transcriptional regulation of interleukin-2 gene expression by CD69-generated signals. Eur J Immunol 23:2993
7. Deblandre GA, Leo O, Huez GA, Wathelet MG (1992) CD69 is expressed on Daudi cells in response to interferon-α. Cytokine 4:36
8. DeHoratius RJ, Hosea JM, Van Epps DE, Reed WP, Edwards WS, Williams RC (1977) Immunologic function in humans before and after hyperthermia and chemotherapy for disseminated malignancy. J Natl Cancer Inst 58:673
9. Eberl G, Lees R, Smiley ST, Taniguchi M, Grusby MJ, MacDonald HR (1999) Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J Immunol 162:6410
10. Feyerabend T, Wiedemann GJ, Richter E, Hegewisch-Becker S (1999) Hyperthermia as an adjunct to the standard treatment of neoplastic diseases: Few cures but some advance. Onkologie 22:122
11. Gibbons DC, Evans TG (1996) CD69 expression after antigenic stimulation. Cytometry 23:260
12. + cell activation to a major mastocytoma rejection antigen, P815AB: Requirement for tumor helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol 25:2797
13. Hamann J, Fiebig H, Strauss M (1993) Expression cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain. J Immunol 150:4920
14. Hammond KJ, Pelikan SB, Crowe NY, Randle-Barrett E, Nakayama T, Taniguchi M, Smyth MJ, van Driel IR, Scollay R, Baxter AG, Godfrey DI (1999) NKT cells are phenotypically and functionally diverse. Eur J Immunol 29:3768
15. Hara T, Jung LKL, Bjorndahl JM, Fu SM (1986) Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens. J Exp Med 164:1988
16. Hegewisch-Becker S, Gruber Y, Corovic A, Pichlmeier U, Atanackovic D, Nierhaus A, Hossfeld DK (2002) Whole body hyperthermia (WBH, 41.8°C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: A phase II study. Ann Oncol 13:1197
17. Hettinga JV, Lemstra W, Meijer C, Mulder NH, Konings AW, de Vries EG, Kampinga HH (1994) Hyperthermia potentiation of cisplatin toxicity in a human small cell lung carcinoma cell line and a cisplatin resistant subline. Int J Hyperthermia 10:795
18. Hofmann B, Nishanian P, Fahey JL, Esmail I, Jackson AL, Detels, R, Cumberland W (1991) Serum increases and lymphoid cell surface losses of IL-2 receptor CD25 in HIV infection: Distinctive parameters of HIV-induced change. Clin Immunol Immunopathol 61:212
19. Jassoy C, Harrer T, Rosenthal T, Navia BA, Worth J, Johnson RP, Walker BD (1993) Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-α), and TNF-β when they encounter their target antigens. J Virol 67:2844
20. + T cells expressing NK cell receptors in influenza A virus-infected mice. J Immunol 165:4964
21. Lanier LL., My Le, Civin CI, Loken MR, Phillips JH (1986) The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136:4480
22. Lanier LL, Buck DW, Rhodes L, Ding A, Evans E, Barney C, Phillips JH (1988) Interleukin-2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J Exp Med 167:1572
23. + and CD4-8- T cells in mice and humans. J Exp Med 180:1097
24. Lanzavecchia A (1993) Identifying strategies for immune intervention. Science 260:937
25. López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sanchez-Mateos P, Sanchez-Madrid F (1993) Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 178:537
26. López-Cabrera M, Munoz E, Blázquez MV, Ursa MA, Santis AG, Sanchez-Madrid F (1995) Transcriptional regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis factor-α-responsive elements. J Biol Chem 270:21545
27. Mardiney III M, Brown MR, Fleisher TA. Measurement of T-cell CD69 expression: A rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. Cytometry 26:305
28. Marzio R, Mauel J, Betz-Corradin S (1999) CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol 21:565
29. Mazzocchi A, Anichini A, Castelli C, Sensi M, Poli F, Russo C, Parmiani G (1990) T lymphocytes can mediate lysis of autolo-gous melanoma cells by multiple mechanisms: Evidence with a single T cell clone. Cancer Immunol Immunother 32:13
30. Michelangeli VP, Heyma P, Colman PG, Ebeling PR (1997) Evaluation of a new, rapid and automated immunochemiluminometric assay for the measurement of serum intact parathyroid hormone. Ann Clin Biochem 34:97
31. Moretta A, Poggi A, Pende D, Tripodi G, Orengo AM, Pella N, Augugliaro R, Bottino C, Ciccone E, Moretta L (1991) CD69-mediated pathway of lymphocyte activation: Anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressiong T cell receptor α/β. J Exp Med 174:1393
32. Nakamura S, Sung SSJ, Bjorndahl JM, Fu SM (1989) Human T cell activation. IV. T cell activation and proliferation via the early activation antigen EA 1. J Exp Med 169:677
33. Nelson BH, Willerford DH (1998) Biology of the interleukin-2 receptor. Adv Immunol 70:1
34. Neri Serneri GG, Prisco D, Martini F, Gori AM, Brunelli T, Poggesi L, Rostagno C, Gensini GF, Abbate R (1997) Acute T-cell activation is detectable in unstable angina. Circulation 95:1806
35. + T cells. Immunology 103:281
36. + T cells which increase at tumour sites in patients with colorectal cancer. Clin Exp Immunol 102:159
37. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumor. J Exp Med 187:693
38. Phillips JH., Lanier LL (1986) Dissection of the lymphocyte-activated killer phenomenon. J Exp Med 164:814
39. + T cells closely correlates with CD56 surface expression. J Immunol 164:1148
40. Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H (2000) Crucial role of TNF-α in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 164:3645
41. Prin L, Plumas J, Gruart V, Loiseau S, Adalbert D, Ameisen JC, Vermersch A, Fenaux P, Bletry O, Capron M (1991) Elevated serum levels of soluble interleukin-2 receptor: A marker of disease activity in the hypereosinophilic syndrome. Blood 78:2626
42. Rietbroek RC, van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, Veenhof CH (1997) Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 123:6
43. Risso A, Smilovich D, Capra MC, Baldissarro I, Yan G, Bargellesi A, Cosulich ME (1991) CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression. J Immunol 146:4105
44. Robins HI., Cohen JD, Schmitt C, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, d'Oleire F, Longo W, Heiss C et al (1993) Phase I clinical trial of carboplatin and 41.8°C whole body hyperthermia in cancer patients. J Clin Oncol 11:1787
45. Robins HI, Kutz M, Wiedemann GJ, Katschinski DM, Paul D, Grosen E, Tiggelaar CL, Spriggs D, Gillis W, d'Oleire F (1995) Cytokine induction by 41.3°C whole body hyperthermia. Cancer Lett 97:195
46. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172
47. Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 113:619
48. + lymphocyte subsets and its relationship with the phenotype of responding T-cells. Cytometry 38:95
49. Sánchez-Mateos P, Sánchez-Madrid F (1991) Structure-function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69. Eur J Immunol 21:2317
50. Santin AD, Hermonat, PL, Ravaggi, A (2000) Effects of concurrent cisplatinum administration during radiotherapy vs radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 48:997
51. Santis AG, Campanero MR, Alonso JL, Tugores A, Alonso MA, Yague E, Pivel JP, Sanchez-Madrid F (1992) Tumor necrosis factor-α production induced in T lymphocytes through the AIM/CD69 activation pathway. Eur J Immunol 22:1253
52. Schafhausen P, Panse J, Nierhaus A, Meissner-Kuck C, Lehmann C, Hegewisch-Becker S (1998) Whole body hyperthermia mobilizes natural killer cells (NK-cells) in the peripheral blood of cancer patients. Blood 92 (1):63b
53. + T cells. J Immunol 164:2009
54. Smyth MJ, Norihisa Y, Ortaldo JR (1992) Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets. J Immunol 148:55
55. + T cell subsets. J Immunol 151:740
56. Speiser DE, Valmori D, Rimoldi D, Pittet MJ, Lienard D, Cerundolo V, MacDonald HR, Cerottini JC, Romero P (1999) CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 20:1990
57. + T cells in patients with malignancy. Clin Exp Immunology 97:522
58. Testi R, Phillips JH, Lanier LL (1989) Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. J Immunol 142:1854
59. Werfel T, Boeker M, Kapp A (1997) Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspensions. Allergy 52:465
60. Westermann AM, Grosen EA, Katschinski DM, Jager D, Rietbroek R, Schink JC, Tiggelaar, CL, Jager E, Zum Vorde sive Vording P, Neuma A, Van Dijk JD, Wiedemann GJ, Robins HI (2001) A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur J Cancer 37:1111
61. Wiedemann GJ, Robins HI, Gutsche S, Mentzel M, Deeken M, Katschinski DM, Eleftheriadis S, Crahe R, Weiss C, Storer B, Wagner T (1996) Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8°C whole-body hyperthermia in patients with refractory sarcoma. Eur J Cancer 32A:888
62. Wiedemann GJ, Katschinski DM, Westermann AM, Jager D, Zum vorde sive Vording P, Van Dijk J, Bailey H, Fine J, Longo W, Bakhshandeh A, Grosen E, Robins HI (2000) A systemic hyperthermia oncologic working group trial: Ifosfamide (IFO), carboplatin (CBDCA) and etoposide (VP-16) combined with Aquaterm induced 41.8°C whole body hyperthermia (WBH) for refractory sarcoma. ASCO Proceedings 19:562a
63. Ziegler SF, Ramsdell F, Hjerrild KA, Armitage RJ, Grabstein KH, Hennen KB, Farrah T, Fanslow WC, Shevach EM, Alderson MR (1993) Molecular characterization of the early activation antigen CD69: A type II membrane glycoprotein related to a family of natural killer cell cativation antigens. Eur J Immunol 23:1643